Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competitor Novo Nordisk slashing prices on their famed Ozempic and Wegovy, not to mention the influx of cost-effective semaglutide generics. Despite this, Lilly remains optimistic about the distinct advantages Mounjaro brings to its users.